Peri-implant Bone Formation of Grafted Sites Around Hydrophilic and Non-hydrophilic Dental Implants
Launched by UNIVERSITY HOSPITAL, GENEVA · Jun 10, 2024
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different types of dental implant surfaces affect the healing of bone when implants are placed after tooth extractions. Specifically, the study will compare two types of implants: one with a standard surface and another with a surface designed to attract more moisture (hydrophilic). Researchers want to understand if these surface differences can help the bone grow better around the implant, which is important for keeping the implant stable and functional.
To participate in this study, individuals must be at least 18 years old and in generally good health, with healthy teeth near the extraction site. They should be scheduled for a tooth extraction and need a bone graft before getting a dental implant. However, those with certain health issues, such as uncontrolled diabetes or a history of cancer treatment, as well as heavy smokers and pregnant women, will not be eligible. Participants can expect to receive a bone graft after their tooth extraction and will be randomly assigned to one of the two implant types. The study will last for three years and aims to gather valuable information on how these implant surfaces influence bone healing.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient age ≥ 18 years
- • Patients with a diagnosed indication for single tooth extraction and scheduled for consented replacement by an implant-based restoration requiring prior bone augmentation
- • Only patients displaying periodontally healthy teeth adjacent to the extracted teeth shall be included (probing depth (PD) \< 4mm, no bleeding on probing (BOP)
- • Patients must be physically and psychologically able to undergo implant surgery and restorative procedures (American Academy of Anesthesiologist class I or II)
- Exclusion Criteria:
- • Presence of any general contra-indication related to implant therapy
- • Heavy smokers ( ≥10 cigarettes/day)
- • Patients displaying a history of uncontrolled metabolic disorders (e.g. diabetes mellitus)
- • Patients with a history of malignancy, radiotherapy, or chemotherapy
- • Pregnant or breast feeding patients
- • Patients with a history of immunodeficiencies
- • Patients displaying any metabolic bone disease
- • Patients with disturbed bone or wound healing
- • Patients with untreated or active periodontitis (BOP and PD\>5mm)
- • Extraction sites displaying an absent or defections buccal bone plate
- • Vulnerable patients will be excluded from the study.
About University Hospital, Geneva
The University Hospital of Geneva is a leading academic medical center committed to advancing healthcare through innovative research and clinical excellence. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge medical research with high-quality patient care, fostering a collaborative environment that encourages the translation of scientific discoveries into practical treatments. As a prominent sponsor of clinical trials, the University Hospital of Geneva is dedicated to exploring new therapies and improving patient outcomes, while adhering to the highest ethical standards and regulatory compliance. Its robust infrastructure and expert clinical teams ensure the efficient execution of trials across various medical specialties, contributing significantly to the advancement of global health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Alexandre Perez, Dr
Principal Investigator
University of Geneva
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported